US Stock MarketDetailed Quotes
CLNN Clene
- 0.3851
- -0.0048-1.23%
Trading May 9 10:15 ET
49.46MMarket Cap-939P/E (TTM)
0.4273High0.3851Low132.27KVolume0.3950Open0.3899Pre Close53.06KTurnover0.20%Turnover RatioLossP/E (Static)128.43MShares1.090052wk High11.67P/B25.74MFloat Cap0.250052wk Low--Dividend TTM66.85MShs Float17.8200Historical High--Div YieldTTM10.82%Amplitude0.2500Historical Low0.4010Avg Price1Lot Size
Clene Stock Forum
Sign in to post a comment
$Clene(CLNN.US$ its so wired. how a company is doing great no law suits. no lay off. no debts in rear. but all out of nowhere it just drop. something is very fisher. about stocks. . like what is the answer. and a company get great new contracts. Anyone in the world have a answer????????? we would like to no
1
$Clene(CLNN.US$ With the poster presentation news and NDA approaching? Just may be time to start scaling in here? NFA just thinking outloud ![]()
4
Breakthrough in Multiple Sclerosis Treatment: Clene’s CNM-Au8® Shows Promising Results.
In a significant development for the multiple sclerosis (MS) community, Clene Inc. recently unveiled the results of its Phase 2 VISIONARY-MS long-term extension study at the prestigious 2024 American Academy of Neurology (AAN) Annual Meeting. The findings are nothing short of groundbreaking, demonstrating substantial evidence that...
In a significant development for the multiple sclerosis (MS) community, Clene Inc. recently unveiled the results of its Phase 2 VISIONARY-MS long-term extension study at the prestigious 2024 American Academy of Neurology (AAN) Annual Meeting. The findings are nothing short of groundbreaking, demonstrating substantial evidence that...
$Clene(CLNN.US$ Why not release the news during normal trading hours? 🤔
1
$Clene(CLNN.US$ Clene Highlights Presentation Of Phase 2 VISIONARY-MS Trial Data At 2024 American Academy of Neurology Annual Meeting; Says 'Long-term CNM-Au8 Treatment, Encompassing up to Three Years, Was Well-tolerated; No Significant Safety Findings Were Observed'
Benzinga· 1 min ago
Benzinga· 1 min ago
2
$Clene(CLNN.US$
NEWS
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
Long term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline)
NEWS
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
Long term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline)
3
$Clene(CLNN.US$ fda pls come soon n burn the shortie 😂
$Clene(CLNN.US$
any special news ya hear?
any special news ya hear?
1
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
71873966 : Stocks are pushed by those with the handle via social media to entice retail investors, but the true investors ignore the hype.